Below is the 2021 schedule and agenda for the BIO CEO & Investor Conference.

BIO CEO & Investor Digital Conference
Date
  • Show All
Time
  • Show All
Company Type
  • Show All
Main Therapeutic Focus
  • Show All
Development Phase of Primary Product
  • Show All
Search Sessions
BIO CEO & Investor Digital Conference
Jump to Day
17 Results
Available On-Demand
3 clinical stage assets: AMO-02 in Phase III in Myotonic Dystrophy AMO-01 in Phelan McDermid…
Annovis Bio, Inc. (NYSE American: ANVS) is a clinical-stage, drug platform company addressing…
Aruna Bio, Inc., is the leader in the development of neural exosomes for the treatment of…
Bioasis is a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™…
Cerevance, a private, clinical-stage pharmaceutical company focused on brain diseases, is applying…
Charcot-Marie-Tooth (CMT) is a genetic disease causing peripheral neuropathy. With over 100…
Emerald Health Pharmaceuticals (“EHP”), is a private, clinical-stage biotechnology company…
MetVital is developing a metabolic treatment that reduces free glutamate levels in the central…
NervGen is a publicly traded biotech company dedicated to discovering and developing treatments for…
Neumentum is a privately held pharmaceutical company founded in 2017 focused on non-opioid Pain…
NeuroScientific Biopharmaceuticals (ASX:NSB) is a leading Australian biotech company focused on…
NeuroSigma is commercializing external Trigeminal Nerve Stimulation (eTNS) technology for…
Newron is a biopharmaceutical company focused on the development of novel therapies for patients…
Oligomerix is an emerging biotechnology company focused on developing disease-modifying…
Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the…

Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in…

Vivoryon Therapeutics has an experienced discovery and development team with a strong track record…